First for Women on MSN23d
La La Anthony on Her Plaque Psoriasis: ‘It Doesn't Have To Hold You Back'S ince revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the ...
Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Discover a study that investigates spesolimab, a monoclonal antibody that has been approved as the first GPP-specific therapy ...
Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...
Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...
The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...
Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting showed that the candidate, icotrokinra (JNJ-2113), was associated with ...
The company noted that data from the Phase 3 ICONIC-LEAD study showed once daily icotrokinra demonstrated significant skin clearance ... moderate-to-severe plaque plaque psoriasis or PsO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback